Presbyopia Pipeline: Insights into Novel Pipeline Therapies, Key Pharma Companies, Growth Prospects and Future Presbyopia Pipeline Landscape

DelveInsight's, "Presbyopia Pipeline Insight, 2022," report provides comprehensive insights about 12+ companies and 12+ pipeline drugs in Presbyopia pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Key takeaways from the Presbyopia Pipeline Insight Report

• Presbyopia Pipeline report offers a comprehensive analysis of 12+ key pharma players and 12+key pipeline therapies.
• The leading Presbyopia Companies are working such as Cellix Bio, AbbVie, Novartis, Visus Therapeutics, AbbVie, Allergan, Encore Vision, Ocuphire Pharma, Orasis Pharmaceuticals, Eyenovia, and among others.
• Promising Presbyopia Pipeline therapies such as UNR844-Cl, LaserACE(R), Pilocarpine, AGN-190584, EV06 Ophthalmic Solution, CSF-1, and others.
• The Presbyopia Companies and academics that are working to assess challenges and seek opportunities that could influence Presbyopia R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition.

Request for Sample to know which pharma company is expected to be at the forefront in the coming years, Presbyopia Pipeline Outlook Report @ https://www.delveinsight.com/sample-request/presbyopia-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Presbyopia Overview

Presbyopia is a vision condition in which the shape of the crystalline lens of your eye changes. These changes make it difficult to focus on close objects. Presbyopia may seem to occur suddenly, but sight reduction occurs over several years. Presbyopia usually becomes noticeable in the early to mid-40s, but the reduction of your focus starts as early as childhood. Some signs of presbyopia include holding reading materials at arm's length, blurred vision at normal reading distance and eye fatigue along with headaches when doing close work. Presbyopia happens naturally in people as they age. The eye is not able to focus light directly on to the retina due to the hardening of the natural lens. Aging also affects muscle fibers around the lens making it harder for the eye to focus on up close objects. The ineffective lens causes light to focus behind the retina, causing poor vision for objects that are up close.

Recent Developmental Activities in the Presbyopia Pipeline

• In August 2020, Eyenovia entered into an exclusive license agreement with Arctic Vision to develop and commercialize MicroPine (Atropine micro formulation) and MicroLine (pilocarpine micro formulation) in China, Hong Kong, Macau and Taiwan and South Korea.
• In February 2021, Allergan submitted a New Drug Application to the Food and Drug Administration for investigational AGN-190584 (pilocarpine 1.25%) ophthalmic solution for the treatment of presbyopia. The FDA is expected to act on the NDA by the end of 2021.

Presbyopia Pipeline Report

In the Presbyopia Pipeline Report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Presbyopia collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Presbyopia Emerging Drugs: Profile

CSF-1: Orasis Pharmaceuticals
CSF-1 is a novel presbyopia corrective eye drop being developed to improve the quality of life for people with presbyopia. CSF-1 is a preservative-free solution that contains a proprietary combination of low-dose pilocarpine and multi-faceted vehicle. Clinical trial results to date have demonstrated significant improvements in near vision and an excellent safety profile in people with presbyopia. In the Phase 3 studies, CSF-1 achieved statistically significant distance-corrected near visual acuity (DCNVA) and no loss of 1-line or more in distance or night vision.

UNR844-Cl: Novartis
UNR844-Cl is an ester of naturally occurring R-lipoic acid and choline. Previously called EV06 ophthalmic solution, UNR844 targets directly the flexibility and accommodative ability of the crystalline lens. It breaks disulfide bonds, which are thought to harden the lens over time. By disrupting these bonds, the lens becomes more elastic and regains some functionality.

For more information on Presbyopia Emerging drugs, visit Presbyopia Clinical Trials Analysis Report @ https://www.delveinsight.com/sample-request/presbyopia-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Presbyopia Pipeline Therapeutics Assessment

There are approx. 12+ key companies which are developing the therapies for Presbyopia. The Presbyopia Companies which have their Presbyopia drug candidates in the most advanced stage, i.e. phase III include, Orasis Pharmaceuticals.

Scope of the Presbyopia Pipeline Insight Report

• Coverage- Global
• Presbyopia Companies- Cellix Bio, AbbVie, Novartis, Visus Therapeutics, AbbVie, Allergan, Encore Vision, Ocuphire Pharma, Orasis Pharmaceuticals, Eyenovia, and among others.
• Presbyopia Pipeline Therapies- UNR844-Cl, LaserACE(R), Pilocarpine, AGN-190584, EV06 Ophthalmic Solution, CSF-1, and others.
• Presbyopia Emerging Therapies, Unmet Needs, Analyst Views

Table of Content
1. Introduction
2. Presbyopia Executive Summary
3. Presbyopia: Overview
4. Presbyopia Pipeline Therapeutics
5. Presbyopia Therapeutic Assessment
6. Presbyopia - DelveInsight's Analytical Perspective
7. Late Stage Products (Phase III)
8. CSF-1: Orasis Pharmaceuticals
9. Drug profiles in the detailed report…..
10. Mid Stage Products (Phase II)
11. UNR844-Cl: Novartis
12. Drug profiles in the detailed report…..
13. Early Stage Products (Phase I/II)
14. Drug name: Company name
15. Drug profiles in the detailed report…..
16. Preclinical and Discovery Stage Products
17. Drug name: Company name
18. Drug profiles in the detailed report…..
19. Inactive Products
20. Presbyopia Key Companies
21. Presbyopia Key Products
22. Presbyopia- Unmet Needs
23. Presbyopia- Market Drivers
24. Presbyopia Market Barriers
25. Presbyopia- Future Perspectives and Conclusion
26. Presbyopia Analyst Views
27. Presbyopia Key Companies
28. Appendix

Key Questions

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing Presbyopia drugs?
• How many Presbyopia drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Presbyopia?
• What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Presbyopia therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Presbyopia and their status?
• What are the key designations that have been granted to the emerging drugs?

Discover more about the scope of Presbyopia Emerging Drugs Report @ https://www.delveinsight.com/report-store/presbyopia-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Contact Us
Yash Bhardwaj
info@delveinsight.com

About Us
DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the healthcare domain and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.

This release was published on openPR.